- Conditions
- Cystic Fibrosis-related Diabetes
- Interventions
- iLet Bionic Pancreas System (BP), Usual Care (UC)
- Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Atlanta, Georgia + 13 more
Institution Directory
Clinical trials at University of Colorado Anschutz
Sites in Aurora, CO
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1010
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Colorado Anschutz, Aurora, CO
Additional filters apply within this campus.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 289–300 of 1,010 matching trials with a site at University of Colorado Anschutz, Aurora, CO.
Live ClinicalTrials.gov results.
Live official records
Belimumab With Rituximab for Primary Membranous Nephropathy
NCT03949855
Status at this site: Recruiting
- Conditions
- Membranous Nephropathy, Nephrotic Syndrome
- Interventions
- Belimumab, Placebo for Belimumab, Rituximab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
NCT05135559
Site status not listed — check the official record
- Conditions
- Haemophilia A and B With and Without Inhibitors
- Interventions
- Concizumab
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 19
- States / cities
- San Diego, California • Aurora, Colorado • Orlando, Florida + 14 more
Study of ALK-001 on the Progression of Stargardt Disease
NCT07419334
Status at this site: Recruiting
- Conditions
- Stargardt Disease
- Interventions
- ALK-001, Placebo
- Drug
- Lead sponsor
- Alkeus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 8 Years to 45 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 11 more
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562
Site status not listed — check the official record
- Conditions
- Systemic Sclerosis
- Interventions
- BMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab, Rituximab, Nintedanib
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Denver, Colorado + 14 more
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796
Status at this site: Recruiting
- Conditions
- Neoplasms
- Interventions
- Gene-modified (GM) T cell therapy
- Genetic
- Lead sponsor
- Celgene
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2043
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
NCT06900595
Status at this site: Recruiting
- Conditions
- Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma, Stage III Adrenal Cortical Carcinoma AJCC v8, Stage IV Adrenal Cortical Carcinoma AJCC v8, Unresectable Adrenal Cortical Carcinoma
- Interventions
- Biospecimen Collection, Cabozantinib, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 81
- States / cities
- Phoenix, Arizona • La Jolla, California • Madera, California + 60 more
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT05327686
Status at this site: Recruiting
- Conditions
- Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
- Interventions
- Avelumab, Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Stereotactic Ablative Radiotherapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 323
- States / cities
- Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 248 more
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877
Site status not listed — check the official record
- Conditions
- Endometrial Neoplasms
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449
Site status not listed — check the official record
- Conditions
- Multiple Sclerosis, Primary Progressive
- Interventions
- Fenebrutinib, Ocrelizumab, Placebo matched to ocrelizumab, Placebo matched to fenebrutinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 985 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 43
- States / cities
- Homewood, Alabama • Berkeley, California • Fullerton, California + 40 more
Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients With Brain Metastasis That Has Been Removed by Surgery
NCT04114981
Site status not listed — check the official record
- Conditions
- Metastatic Malignant Neoplasm in the Brain
- Interventions
- Single Fraction Stereotactic Radiosurgery, Fractionated Stereotactic Radiosurgery, Quality-of-Life Assessment, Questionnaire Administration
- Radiation · Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 223
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 180 more
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
NCT02584933
Site status not listed — check the official record
- Conditions
- ALK Positive Malignancies
- Interventions
- ceritinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 5
- States / cities
- Fayetteville, Arkansas • Loma Linda, California • Aurora, Colorado + 2 more
About this University of Colorado Anschutz institution page
- What this page lists
- ClinicalTrials.gov records that list University of Colorado Anschutz in Aurora, CO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
- Site status
- A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages, browse by condition, or browse by U.S. city.